Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1 medication. In a letter to Lilly CEO David Ricks, provided first to The Hill, Gallego wrote that “substantial questions remain” pertaining to the deal that the White House struck with…
